Published in final edited form as:

Nature. 2012 August 30; 488(7413): 652–655. doi:10.1038/nature11333.

Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2

Claudia A. Doege¹, Keiichi Inoue¹, Toru Yamashita¹, David B. Rhee¹, Skylar Travis¹, Ryousuke Fujita¹, Paolo Guarnieri^{2,3}, Govind Bhagat^{1,3}, William B. Vanti¹, Alan Shih⁴, Ross L. Levine⁴, Sara Nik⁵, Emily I. Chen^{5,6}, and Asa Abeliovich¹

¹Departments of Pathology and Cell Biology and Neurology, Taub Institute for Aging, Columbia University, New York, New York 10032, USA

²Biomedical Informatics Shared Resources, Bioinformatics Division, Columbia University, New York, New York 10032, USA

³Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA

⁴Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10016, USA

⁵Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York 11794, USA

⁶Stony Brook University Proteomics Center, School Of Medicine, Stony Brook, New York 11794, USA

Abstract

Somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) by using the pluripotency factors Oct4, Sox2, Klf4 and c-Myc (together referred to as OSKM)¹. iPSC reprogramming erases somatic epigenetic signatures—as typified by DNA methylation or histone modification at silent pluripotency loci—and establishes alternative epigenetic marks of embryonic stem cells (ESCs)². Here we describe an early and essential stage of somatic cell reprogramming, preceding the induction of transcription at endogenous pluripotency loci such as *Nanog* and *Esrrb*. By day 4 after transduction with OSKM, two epigenetic modification factors necessary for iPSC generation, namely poly(ADP-ribose) polymerase-1 (Parp1) and ten-eleven translocation-2 (Tet2), are recruited to the *Nanog* and *Esrrb* loci. These epigenetic modification factors seem to have complementary roles in the establishment of early epigenetic marks during

Reprints and permissions information is available at www.nature.com/reprints.

Correspondence and requests for materials should be addressed to A.A. (aa900@columbia.edu).

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Author Contributions C.A.D. and A.A. designed the experiments and analysed data. C.A.D., D.B.R., S.T., R.F. and W.B.V. conducted molecular and cellular experiments. T.Y., G.B. and K.I. performed and analysed murine *in vivo* studies. R.L.L. and A.S. supplied essential reagents. P.G. performed bioinformatics analyses. S.N. and E.I.C. conducted proteomics. C.A.D. and A.A. wrote the manuscript.

The authors declare no competing financial interests.

Readers are welcome to comment on the online version of this article at www.nature.com/nature.

somatic cell reprogramming: Parp1 functions in the regulation of 5-methylcytosine (5mC) modification, whereas Tet2 is essential for the early generation of 5-hydroxymethylcytosine (5hmC) by the oxidation of 5mC (refs ^{3,4}). Although 5hmC has been proposed to serve primarily as an intermediate in 5mC demethylation to cytosine in certain contexts^{5–7}, our data, and also studies of Tet2-mutant human tumour cells⁸, argue in favour of a role for 5hmC as an epigenetic mark distinct from 5mC. Consistent with this, Parp1 and Tet2 are each needed for the early establishment of histone modifications that typify an activated chromatin state at pluripotency loci, whereas Parp1 induction further promotes accessibility to the Oct4 reprogramming factor. These findings suggest that Parp1 and Tet2 contribute to an epigenetic program that directs subsequent transcriptional induction at pluripotency loci during somatic cell reprogramming.

We performed a functional screen for epigenetic modification factors that promote OSKM-mediated somatic cell reprogramming. Overexpression of a single pool of 29 candidate epigenetic modification factors, selected on the basis of a proteomic analysis of iPSCs (Fig. 1a–c and Supplementary Tables 1 and 2), promoted iPSC colony production in mouse embryonic fibroblast (MEF) cultures transduced with OSKM (OSKM-MEFs; relative to green fluorescent protein vector control transduced MEF; Fig. 1d). Candidate epigenetic modification factors were retested in successive subpools, and Parp1 was identified as a potent inducer of OSKM-MEF reprogramming (Fig. 1d). iPSCs generated by OSKM-MEFs with Parp1 were confirmed as pluripotent by immunocytochemistry (Supplementary Fig. 2a), gene expression (Supplementary Fig. 2b–f and Supplementary Table 3) and pyrosequencing (Supplementary Fig. 2g–i and Supplementary Table 4) analyses at multiple pluripotency loci. Parp1 overexpression did not alter the proliferation rate of transduced cultures (as determined by bromodeoxyuridine (BrdU) incorporation; Supplementary Fig. 2j).

Parp1 is a broadly expressed nuclear protein involved in the detection and repair of DNA damage, the remodelling of chromatin and the regulation of transcription⁹. A time course of endogenous *Parp1* expression revealed detectable levels even in wild-type (WT) MEFs and a peak at day 4 (d4) after transduction with OSKM (Fig. 1e, f and Supplementary Figs 2k and 3a), thus preceding expression of the endogenous pluripotency loci including *Nanog*, *Oct4* and *Esrrb* (Fig. 1f and Supplementary Fig. 3b). Immunocytochemistry analysis at d4 after transduction of WT MEFs with OSKM (WT d4-OSKM-MEFs) demonstrated Parp1 accumulation in a majority of nuclei in comparison with d4 control vector-transduced MEFs (WT d4-CONT-MEFs; Fig. 1g). The increased accumulation of Parp1 holoprotein during reprogramming was not paralleled by a corresponding accumulation of cleaved Parp1, a marker of apoptosis (Supplementary Fig. 3a).

In view of the effect of Parp1 overexpression in somatic cell reprogramming, we next tested the impact of Parp1 deficiency. Reprogramming of iPSCs was suppressed in the context of *Parp1*^{−/−} OSKM-MEFs relative to WT OSKM-MEFs (Fig. 2a and Supplementary Fig. 2k, l). Resupplying WT Parp1 partly rescued iPSC generation in *Parp1*^{−/−} OSKM-MEFs. In contrast, expression of Parp1 mutants^{10,11}, compromising either the catalytic activity or the DNA-binding activity, failed to rescue iPSC generation, indicating that both activities are required for iPSC reprogramming (Fig. 2a and Supplementary Fig. 2l).

The early expression and functional role of endogenous *Parp1* in the reprogramming process suggested the possibility of a direct interaction at pluripotency loci. Consistent with this notion, chromatin immunoprecipitation (ChIP) at the *Nanog* and *Esrrb* pluripotency loci, in the transcription start site regions (Supplementary Table 5), demonstrated increased Parp1 binding in d4-OSKM-MEFs and iPSCs (compared with d4-CONT-MEFs; Fig. 2b, c and Supplementary Fig. 3g, h, k).

Parp1 has been broadly implicated in the regulation of epigenetic remodelling events^{7,12}, but its role during the reprogramming of pluripotency loci is unclear. We therefore investigated the impact of modified Parp1 expression on two distinct forms of cytosine methylation at pluripotency loci, 5mC and 5hmC, during somatic cell reprogramming. 5hmC is a more recently described DNA modification that has been suggested to participate in the maintenance of pluripotency at regulatory elements^{5,13–17} in ESCs, but its role during somatic cell reprogramming has not previously been described. We quantified total cytosine methylation (5mC plus 5hmC; either by *HpaII* digestion sensitivity assays or pyrosequencing of bisulphite-treated DNA) or 5hmC alone (either by *MspI* sensitivity assay (glucosylation-coupled methylation-sensitive quantitative polymerase chain reaction; GlucMS-qPCR)^{16,18} or hydroxymethylated DNA immunoprecipitation (hMeDIP); see Supplementary Tables 6 and 7 and Supplementary Methods) at regulatory regions of the *Nanog* or *Esrrb* loci. Both d4-OSKM-MEFs and iPSCs showed a significant and consistent increase in 5hmC relative to d4-CONT-MEFs (Fig. 2d and Supplementary Fig. 3c, d, n–q) at the pluripotency loci. In contrast to 5hmC, 5mC was not accumulated at the early time point (in d4-OSKM-MEFs, relative to d4-CONT-MEFs) at either locus (Fig. 2e and Supplementary Fig. 3j, m). The two pluripotency loci differed with respect to the overall pattern of 5mC during reprogramming, as previously described^{2,19}: the *Nanog* locus showed a canonical pattern of hypermethylation (elevated 5mC) in MEFs and became demethylated (low 5mC) in reprogrammed iPSCs (Fig. 2e and Supplementary Fig. 3e, f), whereas the *Esrrb* locus showed a relatively low level of methylation even in MEFs, and remained hypomethylated in fully reprogrammed iPSCs (Supplementary Fig. 3i, j, l, m). Thus among these pluripotency loci, 5hmC rather than 5mC seemed to be an early and predictive epigenetic mark for subsequent activation. Immunocytochemistry analysis with an antibody against 5hmC showed increased nuclear staining in most cells in d4-OSKM-MEFs (relative to d4-CONT-MEF cultures; Fig. 3a).

We next sought to determine the role of Parp1 in the regulation of 5hmC and 5mC epigenetic marks at the pluripotency loci. Parp1 deficiency (which suppressed iPSC reprogramming) led to a consistent, large increase in 5mC accumulation in *Parp1*^{−/−} d4-OSKM-MEFs, relative to WT d4-OSKM-MEF cultures at both the *Nanog* and *Esrrb* loci (Fig. 2e and Supplementary Fig. 3j, m). The increased 5hmC in WT d4-OSKM-MEFs was not suppressed in *Parp1*^{−/−} d4-OSKM-MEFs; rather, in the context of Parp1 deficiency, 5hmC induction seemed similar to that of WT cells, for example at the *Nanog* locus, or modestly further increased, for example at the *Esrrb* locus (Fig. 2d and Supplementary Fig. 3d, n–q). Parp1 overexpression (which promoted iPSC reprogramming) did not consistently modify 5mC or 5hmC in d4-OSKM-MEFs, although a modest increase in 5hmC levels was observed at the *Esrrb* locus but not at the *Nanog* locus (Fig. 2d and Supplementary Fig. 3o,

q). Taken together, these data implicate Parp1 in the regulation of 5mC; in contrast, we speculate that the variable impact of Parp1 on 5hmC may be indirect.

Given the potential role of 5hmC early in somatic cell reprogramming, we obtained an expression time-course analysis of the TET enzymes, a family of Fe II and 2-oxoglutarate-dependent enzymes that generate 5hmC from 5mC (ref. 4). Expression of *Tet2*, but not *Tet1* or *Tet3*, was significantly induced in WT d4-OSKM-MEFs and remained elevated in iPSCs (Fig. 3b and Supplementary Fig. 4a). Consistent with a functional role for Tet2, short hairpin RNA (shRNA)-mediated *Tet2* knockdown (KD; Supplementary Table 8) abolished iPSC colony formation (Fig. 3c and Supplementary Fig. 4b, c). ChIP analysis with an antibody against Tet2 showed a direct interaction with the *Nanog* and *Esrrb* pluripotency loci in WT d4-OSKM-MEFs; this was not altered in *Parp1*^{-/-} d4-OSKM-MEFs (Fig. 3d, e and Supplementary Fig. 4d, e, l, m). Furthermore, *Tet2* KD in d4-OSKM-MEFs suppressed the typical induction of 5hmC at both the *Nanog* and *Esrrb* pluripotency loci (Fig. 3f, g and Supplementary Fig. 4f, g). In contrast, the effect of *Tet2* KD in d4-OSKM-MEFs on 5mC seemed variable: 5mC seemed to be decreased at the *Nanog* locus but mildly increased at the *Esrrb* locus (which is typically hypomethylated even in MEFs¹⁹; Fig. 3h and Supplementary Fig. 4h–k). Given the early induction of 5hmC but not 5mC at the pluripotency loci, as well as the consequences of Tet2 deficiency in preventing transcriptional activation and 5hmC induction even in the absence of 5mC reduction, these data support a primary role for 5hmC as a distinct epigenetic mark in the somatic cell reprogramming process, and argue against an alternative model in which 5hmC functions simply as an intermediate in the 5mC demethylation process²⁰. Epigenetic marks with 5hmC may recruit select chromatin modification factors to the pluripotency loci²¹.

To further probe the roles of Tet2 and Parp1 in early epigenetic events, we evaluated the chromatin state of the *Nanog* and *Esrrb* loci in d4-OSKM-MEFs. ChIP analysis revealed an enrichment in the occupancy of these loci by the activation-associated marker histone H3 lysine 4 dimethylation (H3K4me2)^{22,23} and a parallel decrease in the transcriptional-silencing-associated marker histone H3 lysine 27 trimethylation (relative to d4-CONT-MEFs; H3K27me3 (refs ^{24–26}); Fig. 4a–d and Supplementary Fig. 5a, b). Deficiency of either Parp1 or Tet2 diminished the H3K4me2 chromatin mark at the pluripotency loci of d4-OSKM-MEFs (Fig. 4a, c and Supplementary Fig. 5a). The effects on H3K27me3 were variable: Parp1 deficiency did not significantly alter H3K27me3 at either locus, whereas *Tet2* KD led to a decrease at the *Nanog* locus but not at the *Esrrb* locus (Fig. 4b, d and Supplementary Fig. 5b). We speculated that altered chromatin states in d4-OSKM-MEFs may affect chromatin accessibility at the pluripotency loci, for example to the transduced Oct4 pluripotency factor. Oct4 occupancy, as quantified by ChIP of d4-OSKM-MEFs, was significantly diminished in the context of Parp1 deficiency at both pluripotency loci, whereas *Tet2* KD did not diminish Oct4 occupancy (Fig. 4e, g and Supplementary Fig. 5c). Consistent with this, Parp1 overexpression potentiated Oct4 binding at both pluripotency loci of d4-OSKM-MEFs (Fig. 4e, g and Supplementary Fig. 5c). Furthermore, Parp1 overexpression robustly promoted exogenous Oct4 binding to the pluripotency loci even in the absence of transduction of the other pluripotency factors necessary for somatic cell reprogramming (d4-OMEFs without SKM; Fig. 4f, h and Supplementary Fig. 5d).

Taken together, these data support necessary but distinct roles for Tet2 and Parp1 in the regulation of epigenetic marks and local chromatin structure at pluripotency loci during an early stage of somatic cell reprogramming that precedes their transcriptional activation (Supplementary Fig. 1a, b). The data further suggest that 5hmC, generated by Tet2, does not simply represent an intermediate in the 5mC demethylation process, but functions as an epigenetic mark, possibly recruiting *trans*-acting factors that promote chromatin remodelling^{4,21}. The induction of *Parp1* and *Tet2* gene expression early in the course of reprogramming may reflect their direct activation by OSKM factors (Supplementary Fig. 5e, f)²⁷. Finally, loss of Tet2 function is strongly implicated in human malignancies⁸, and thus Tet2-mediated chromatin remodelling may affect tumour risk associated with potential iPSC therapies.

METHODS SUMMARY

Cell culture and generation of iPSCs

MEF were prepared from WT or *Parp1*^{-/-} embryonic day 13.5 embryos (129S-*Parp1*^{tm1Zqw/J}; Jackson Laboratories)²⁸. Tail-tip fibroblasts were prepared from WT and *Tet2*^{-/-} mice²⁹. For iPSC generation, MEFs were transduced by incubation with OSKM retroviral supernatants for 24 h as described¹. Subsequently, cells were cultured in ESC medium and samples were collected at the time points indicated. Epigenetic modification factors were cloned into lentiviral vectors (pLenti6.3; Invitrogen) for lentiviral production and subsequent transduction.

Tet2 knockdown

Tet2 knockdown was achieved by using a cocktail of five shRNA lentiviral vectors (Open Biosystems) specific for *Tet2*, or control non-silencing shRNA.

Mass spectrometry

Multidimensional protein identification technology (MudPIT) was performed to analyse nuclear fractions of MEFs, iPSC clones and ESC clones as detailed in Supplementary Methods.

Chromatin immunoprecipitation

ChIP was performed with the Magnify kit (492024; Invitrogen) and the following antibodies: anti-dimethyl K4 of H3 (2 µg; 07-030; Millipore), anti-trimethyl K27 of H3 (2 µg; ab6002; Abcam), anti-Oct4 (2 µg; sc-8628 X; Santa Cruz), anti-Parp1 (2 µg; sc-74469 X; Santa Cruz), anti-Tet2 (2 µg; sc-136926; Santa Cruz), normal goat IgG (2 µg; 005-000-003; Jackson ImmunoResearch), normal rabbit IgG (1 µg; Magnify; Invitrogen) and normal mouse IgG (1 µg; Magnify; Invitrogen).

Digestion with *HpaII* and *MspI*

Detection of 5hmC and 5mC as percentages of total cytosine species was performed with the EpiMark Kit (E3317S; NEB). The technique has been described in detail in ref. 16.

Pyrosequencing

Genomic DNA (1 µg) was bisulphite-converted with the EZ DNA Methylation Kit (D5001; Zymo Research), followed by amplification by polymerase chain reaction with the PyroMark PCR Kit (978703; Qiagen). PCR products were sequenced with the PyroMark Q24 instrument (Qiagen).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank G. Q. Daley, A. P. Feinberg, A. Doi, R. M. Santella and M. A. Kappil for reagents and for technical assistance with pyrosequencing; A. Califano and A. Lachmann for assistance with the bioinformatics analyses; E. O. Mazzone for assistance with the ChIP analyses; and O. Hobert for critical reading of the manuscript. This work was supported by New York State Stem Cell Science (NYSTEM) grants C024402 and C024403 and National Institutes of Health (NIH) grant RO1 NS064433 to A.A., NYSTEM Institution Development Grant N08G-071 to E.I.C., NIH grant RO1 138424 to R.L.L., and a shared NIH/National Center for Research Resources instrument grant for mass spectrometry, 1 S10RR023680-1.

References

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006; 126:663–676. [PubMed: 16904174]
2. Mikkelsen TS, et al. Dissecting direct reprogramming through integrative genomic analysis. *Nature*. 2008; 454:49–55. [PubMed: 18509334]
3. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. *Science*. 2009; 324:929–930. [PubMed: 19372393]
4. Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science*. 2009; 324:930–935. [PubMed: 19372391]
5. Ito S, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. *Nature*. 2010; 466:1129–1133. [PubMed: 20639862]
6. Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*. 2010; 18:553–567. [PubMed: 21130701]
7. Guo JU, et al. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. *Cell*. 2011; 145:423–434. [PubMed: 21496894]
8. Ko M, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. *Nature*. 2011; 468:839–843.
9. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. *Mol Cell*. 2010; 39:8–24. [PubMed: 20603072]
10. Wacker DA, et al. The DNA binding and catalytic domains of poly(ADP-ribose) polymerase 1 cooperate in the regulation of chromatin structure and transcription. *Mol Cell Biol*. 2007; 27:7475–7485. [PubMed: 17785446]
11. Langelier MF, et al. The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. *J Biol Chem*. 2010; 285:18877–18887. [PubMed: 20388712]
12. Hajkova P, et al. Genome-wide reprogramming in the mouse germ line entails the base excision repair pathway. *Science*. 2010; 329:78–82. [PubMed: 20595612]
13. Williams K, et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. *Nature*. 2011; 473:343–348. [PubMed: 21490601]
14. Pastor WA, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. *Nature*. 2011; 473:394–397. [PubMed: 21552279]

15. Wu H, et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. *Genes Dev.* 2011; 25:679–684. [PubMed: 21460036]
16. Ficiz G, et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. *Nature.* 2011; 473:398–402. [PubMed: 21460836]
17. Wu H, et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. *Nature.* 2011; 473:389–393. [PubMed: 21451524]
18. Davis, T.; Vaisvila, R. High sensitivity 5-hydroxymethylcytosine detection in Balb/C brain tissue; *J Vis Exp.* 2011. p. e2661 <http://dx.doi.org/10.3791/2661>
19. Meissner A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature.* 2008; 454:766–770. [PubMed: 18600261]
20. Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. *Cell.* 2011; 146:866–872. [PubMed: 21925312]
21. Yildirim O, et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. *Cell.* 2011; 147:1498–1510. [PubMed: 22196727]
22. Bernstein BE, et al. Genomic maps and comparative analysis of histone modifications in human and mouse. *Cell.* 2005; 120:169–181. [PubMed: 15680324]
23. Heintzman ND, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. *Nature Genet.* 2007; 39:311–318. [PubMed: 17277777]
24. Bernstein BE, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell.* 2006; 125:315–326. [PubMed: 16630819]
25. Lee TI, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. *Cell.* 2006; 125:301–313. [PubMed: 16630818]
26. Mikkelsen TS, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. *Nature.* 2007; 448:553–560. [PubMed: 17603471]
27. Koh KP, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. *Cell Stem Cell.* 2011; 8:200–213. [PubMed: 21295276]
28. Wang ZQ, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. *Genes Dev.* 1995; 9:509–520. [PubMed: 7698643]
29. Moran-Crusio K, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. *Cancer Cell.* 2011; 20:11–24. [PubMed: 21723200]
30. Smith ZD, Nachman I, Regev A, Meissner A. Dynamic single-cell imaging of direct reprogramming reveals an early specifying event. *Nature Biotechnol.* 2010; 28:521–526. [PubMed: 20436460]

Figure 1. Parp1 promotes OSKM-mediated iPSC generation

a, Diagram of proteomic strategy to identify candidate epigenetic modification (EM) factors. **b**, Unsupervised hierarchical clustering analysis (Spearman rank correlation) of mass spectrometry data from nuclear extracts of MEFs ($n = 3$), iPSCs ($n = 3$) and ESCs ($n = 1$). The scale bar represents the correlation height ($= 1 - \text{Abs}[\text{correlation}]$). **c**, Dual-colour heat map for expression levels of 29 proteins highly enriched in both the iPSC and ESC samples (relative to MEFs). The colour scale bar represents the spectral count. Candidate EM factors were divided into six groups for further functional testing. **d**, Functional screen of candidate EM factors for promotion of somatic cell reprogramming in OSKM-MEFs. EM candidates were transduced together as a single pool of 29 genes, as 6 subpools, or as individual factors from group 6 (as in **c**). Alkaline phosphatase-positive (AP^+) iPSC colonies were counted at day 14 after transduction with OSKM. **e**, Diagram of time-course analyses of iPSC reprogramming. **f**, Gene expression time course of endogenous *Parp1*, *Nanog* and *Oct4*. **g**, Immunocytochemistry analysis of WT or *Parp1*^{-/-} d4-OSKM-MEFs and d4-CONT-MEFs with an antibody against Parp1 (upper panels; red), and counterstained with Sytox nuclear marker (lower panels; green). Increased Parp1 expression in d4-OSKM-MEFs is quantified on the right (Parp1^{HI}; defined as mean plus 2 s.d. or greater than the expression level in d4-CONT-MEFs); modified nuclear morphology apparent in d4-OSKM-MEFs is as described previously³⁰. Results in **d**, **f** and **g** are shown as means and s.d. for three independent experiments. Asterisk, $P < 0.05$; three asterisks, $P < 0.001$.

Figure 2. Parp1 activities during iPSC reprogramming

a, Functional analysis of Parp1 mutants for rescue of iPSC colony formation in *Parp1*^{-/-} OSKM-MEFs. Cultures were transduced with green fluorescent protein (GFP), WT Parp1, or Parp1 mutants encoding a catalytic domain missense mutation (CAT mutant; E988K), deletion of the catalytic domain (ΔCAT), deletion of the DNA-binding and automodification domains (CAT-only), or triple missense mutation of the DNA-binding domain (DBD mutant; C21G/C125G/L139P). Zn, zinc fingers; BRCT, BRCA1 carboxy terminus. **b**, Schematic representation of the *Nanog* locus transcription start site (TSS) region. Indicated are *HpaII*/*MspI* sites (green bars) and amplicons for ‘exon 1/intron 1’ and ‘intron 1’ regions (thick grey lines). bp, base pairs. **c**, Parp1 ChIP analyses of the cultures as indicated, presented as the relative enrichment to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). **d**, Content of 5hmC assessed by GlucMS-qPCR (as a percentage of total cytosine). **e**, Content of 5mC, quantified by subtraction of 5hmC content (as in **d**) from the total methylated cytosine (5mC + 5hmC), as determined by *HpaII* digestion insensitivity; see Supplementary Fig. 3f). Results in **a** and **c–e** are shown as means and s.d. for three independent experiments. Asterisk, $P < 0.05$; two asterisks, $P < 0.01$; three asterisks, $P < 0.001$.

Figure 3. Tet2 is required for 5hmC formation at the *Nanog* locus

a, Immunocytochemistry of d4-OSKM-MEFs and d4-CONT-MEFs with an antibody against 5hmC (ref. 5) (upper panels; red) and counterstained with Sytox nuclear marker (lower panels; green). Representative images show increased 5hmC in d4-OSKM-MEFs, as quantified on the right (5hmC^{HI}, defined as mean plus 2 s.d. or greater above the level in d4-CONT-MEFs). **b**, Time course of *Tet1* and *Tet2* gene expression assessed by qPCR (relative to ESC level). **c**, OSKM-mediated iPSC colony formation assay (AP⁺) in shRNA-mediated *Tet2* knockdown (*Tet2* KD; blue) and non-silencing control shRNA (mock KD; black)-treated MEFs. **d**, Diagram of the *Nanog* locus; regions are the same as in Fig. 2b. **e**, Tet2 ChIP-qPCR at the exon 1/intron 1 amplicon. **f**, **g**, Content of 5hmC in the cultures indicated, assessed by hMeDIP of the exon 1/intron 1 region (**f**, relative to GAPDH) or GlucMS-qPCR intron 1 amplicon (**g**, as a percentage of total cytosine). **h**, Content of 5mC at the intron 1 amplicon, quantified by subtraction of 5hmC (as in **g**) from the total methylated cytosine levels (as in Supplementary Fig. 4k; determined by *Hpa*II sensitivity assay; as a percentage of total cytosine). Results in **a–c** and **e–h** are shown as means and s.d. for three independent experiments. Asterisk, $P < 0.05$; two asterisks, $P < 0.01$; three asterisks, $P < 0.001$.

Figure 4. Impact of Parp1 and Tet2 on chromatin state and Oct4 accessibility at the *Nanog* and *Esrrb* loci

a–d, H3K4me2 (**a**, **c**) and H3K27me3 (**b**, **d**) ChIP-qPCR at *Nanog* or *Esrrb* amplicons in cultures as indicated. **e–h**, Oct4 ChIP-qPCR. Results are shown as means and s.d. for three independent experiments. Asterisk, $P < 0.05$; two asterisks, $P < 0.01$; three asterisks, $P < 0.001$.